| Literature DB >> 34355692 |
Hyae Yon Kweon1, Mi-Ni Lee1,2, Max Dorfel3, Seungwoon Seo1, Leah Gottlieb4,5, Thomas PaPazyan3, Nina McTiernan6, Rasmus Ree6, David Bolton7, Andrew Garcia8, Michael Flory9, Jonathan Crain3, Alison Sebold3, Scott Lyons3, Ahmed Ismail3, Elaine Marchi8, Seong-Keun Sonn1, Se-Jin Jeong10, Sejin Jeon1, Shinyeong Ju11, Simon J Conway12, Taesoo Kim1, Hyun-Seok Kim1, Cheolju Lee11,13, Tae-Young Roh14, Thomas Arnesen6,15,16, Ronen Marmorstein4,5,17, Goo Taeg Oh1, Gholson J Lyon3,8,18,19.
Abstract
Amino-terminal acetylation is catalyzed by a set of N-terminal acetyltransferases (NATs). The NatA complex (including X-linked Naa10 and Naa15) is the major acetyltransferase, with 40-50% of all mammalian proteins being potential substrates. However, the overall role of amino-terminal acetylation on a whole-organism level is poorly understood, particularly in mammals. Male mice lacking Naa10 show no globally apparent in vivo amino-terminal acetylation impairment and do not exhibit complete embryonic lethality. Rather Naa10 nulls display increased neonatal lethality, and the majority of surviving undersized mutants exhibit a combination of hydrocephaly, cardiac defects, homeotic anterior transformation, piebaldism, and urogenital anomalies. Naa12 is a previously unannotated Naa10-like paralog with NAT activity that genetically compensates for Naa10. Mice deficient for Naa12 have no apparent phenotype, whereas mice deficient for Naa10 and Naa12 display embryonic lethality. The discovery of Naa12 adds to the currently known machinery involved in amino-terminal acetylation in mice.Entities:
Keywords: N-terminal acetylation; NAA10; NAA12; developmental biology; embryonic lethality; hydrocephaly; mouse; protein modification
Mesh:
Substances:
Year: 2021 PMID: 34355692 PMCID: PMC8376253 DOI: 10.7554/eLife.65952
Source DB: PubMed Journal: Elife ISSN: 2050-084X Impact factor: 8.713